Historical Valuation
Seres Therapeutics Inc (MCRB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.50. The fair price of Seres Therapeutics Inc (MCRB) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：15.29
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Seres Therapeutics Inc (MCRB) has a current Price-to-Book (P/B) ratio of 3.04. Compared to its 3-year average P/B ratio of 5.55 , the current P/B ratio is approximately -45.29% higher. Relative to its 5-year average P/B ratio of 7.64, the current P/B ratio is about -60.22% higher. Seres Therapeutics Inc (MCRB) has a Forward Free Cash Flow (FCF) yield of approximately -17.05%. Compared to its 3-year average FCF yield of -73.14%, the current FCF yield is approximately -76.69% lower. Relative to its 5-year average FCF yield of -47.32% , the current FCF yield is about -63.97% lower.
P/B
Median3y
5.55
Median5y
7.64
FCF Yield
Median3y
-73.14
Median5y
-47.32
Competitors Valuation Multiple
AI Analysis for MCRB
The average P/S ratio for MCRB competitors is 0.00, providing a benchmark for relative valuation. Seres Therapeutics Inc Corp (MCRB.O) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MCRB
1Y
3Y
5Y
Market capitalization of MCRB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MCRB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MCRB currently overvalued or undervalued?
Seres Therapeutics Inc (MCRB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.50. The fair price of Seres Therapeutics Inc (MCRB) is between NaN to NaN according to relative valuation methord.
What is Seres Therapeutics Inc (MCRB) fair value?
MCRB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Seres Therapeutics Inc (MCRB) is between NaN to NaN according to relative valuation methord.
How does MCRB's valuation metrics compare to the industry average?
The average P/S ratio for MCRB's competitors is 0.00, providing a benchmark for relative valuation. Seres Therapeutics Inc Corp (MCRB) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Seres Therapeutics Inc (MCRB) as of Jan 09 2026?
As of Jan 09 2026, Seres Therapeutics Inc (MCRB) has a P/B ratio of 3.04. This indicates that the market values MCRB at 3.04 times its book value.
What is the current FCF Yield for Seres Therapeutics Inc (MCRB) as of Jan 09 2026?
As of Jan 09 2026, Seres Therapeutics Inc (MCRB) has a FCF Yield of -17.05%. This means that for every dollar of Seres Therapeutics Inc’s market capitalization, the company generates -17.05 cents in free cash flow.
What is the current Forward P/E ratio for Seres Therapeutics Inc (MCRB) as of Jan 09 2026?
As of Jan 09 2026, Seres Therapeutics Inc (MCRB) has a Forward P/E ratio of -1.97. This means the market is willing to pay $-1.97 for every dollar of Seres Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Seres Therapeutics Inc (MCRB) as of Jan 09 2026?
As of Jan 09 2026, Seres Therapeutics Inc (MCRB) has a Forward P/S ratio of 0.00. This means the market is valuing MCRB at $0.00 for every dollar of expected revenue over the next 12 months.